{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:09:06Z","timestamp":1795100946232,"version":"4.10.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and objectives<\/jats:title>\n                <jats:p>The identification of predictors of response to antiCGRP mAbs could favor tailored therapies and personalized treatment plans. This study is aimed at investigating predictors of \u2265\u200950%, \u2265\u200975% and 100% response at 24\u2009weeks in patients with high-frequency episodic (HFEM: 8\u201314\u2009days\/month) or chronic migraine (CM).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a large, multicenter, cohort, real-life study. We considered all consecutive adult patients affected by HFEM or CM who were prescribed antiCGRP mAbs for \u2265\u200924\u2009weeks in 20 headache centers. Patients were interviewed face-to-face using a shared semi-structured questionnaire carefully exploring socio-demographic and clinical characteristics. Patients received subcutaneous erenumab (70\u2009mg or140 mg, monthly), galcanezumab (120\u2009mg monthly, following a 240\u2009mg loading dose), or fremanezumab (225\u2009mg, monthly or 675\u2009mg, quarterly) according to drug market availability, physician\u2019s choice, or patient\u2019s preference. The primary endpoint of the study was the assessment of \u2265\u200950% response predictors at 24\u2009weeks. Secondary endpoints included \u2265\u200975% and 100% response predictors at 24\u2009weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eight hundred sixty-four migraine patients had been treated with antiCGRP mAbs for \u2265\u200924\u2009weeks (erenumab: 639 pts; galcanezumab: 173 pts; fremanezumab: 55 pts). The \u226550% response (primary endpoint) in HFEM was positively associated with unilateral pain (UP)\u2009+\u2009unilateral cranial autonomic symptoms (UAs) (OR:4.23, 95%CI:1.57\u201311.4; <jats:italic>p<\/jats:italic>\u2009=\u20090.004), while in CM was positively associated with UAs (OR:1.49, 95%CI:1.05\u20132.11; <jats:italic>p<\/jats:italic>\u2009=\u20090.026), UP + UAs (OR:1.90, 95%CI:1.15\u20133.16; <jats:italic>p<\/jats:italic>\u2009=\u20090.012), UP + allodynia (OR:1.71, 95%CI:1.04\u20132.83; <jats:italic>p<\/jats:italic>\u2009=\u20090.034), and negatively associated with obesity (OR:0.21, 95%CI:0.07\u20130.64; <jats:italic>p<\/jats:italic>\u2009=\u20090.006). The 75% response (secondary endpoint) was positively associated with UP + UAs in HFEM (OR:3.44, 95%CI:1.42\u20138.31; <jats:italic>p<\/jats:italic>\u2009=\u20090.006) and with UP + UAs (OR:1.78, 95%CI:1.14\u20132.80; <jats:italic>p<\/jats:italic>\u2009=\u20090.012) and UP + allodynia (OR:1.92, 95%CI:1.22\u20133.06; <jats:italic>p<\/jats:italic>\u2009=\u20090.005) in CM. No predictor of 100% response emerged in patients with HFEM or CM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A critical evaluation of headache characteristics indicating peripheral or central sensitization may help in predicting responsiveness to antiCGRP mAbs in HFEM and CM. A more precise pain profiling may represent a steppingstone for a mechanism-based approach and personalized treatment of migraine with compounds targeting specific molecular mechanisms.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01498-6","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T02:02:34Z","timestamp":1667268154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients"],"prefix":"10.1186","volume":"23","author":[{"given":"Piero","family":"Barbanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Egeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Aurilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florindo","family":"d\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Finocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Aguggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Cevoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carnevale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fiorentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Torelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Italian Migraine Registry study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"issue":"9","key":"1498_CR1","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1177\/1060028019835166","volume":"53","author":"SG Garland","year":"2019","unstructured":"Garland SG, Smith SM, Gums JG (2019) Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention. Ann Pharmacother 53(9):933\u2013939","journal-title":"Ann Pharmacother"},{"key":"1498_CR2","doi-asserted-by":"publisher","first-page":"649143","DOI":"10.3389\/fphar.2021.649143","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Chen Y, Song J, You C (2021) Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis. Front Pharmacol 12:649143","journal-title":"Front Pharmacol"},{"key":"1498_CR3","doi-asserted-by":"crossref","unstructured":"Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD  Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. Cephalalgia 41(7):851\u2013864","DOI":"10.1177\/0333102421989601"},{"issue":"1","key":"1498_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","volume":"22","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A et al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 22(1):128. https:\/\/doi.org\/10.1186\/s10194-021-01335-2","journal-title":"J Headache Pain."},{"issue":"3","key":"1498_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/WCO.0000000000000689","volume":"32","author":"M Torres-Ferrus","year":"2019","unstructured":"Torres-Ferrus M, Alpuente A, Pozo-Rosich P (2019) How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective Curr Opin Neurol 32(3):395\u2013404","journal-title":"A patient's perspective Curr Opin Neurol"},{"issue":"5","key":"1498_CR6","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1377\/hlthaff.2017.1624","volume":"37","author":"GS Ginsburg","year":"2018","unstructured":"Ginsburg GS, Phillips KA (2018) Precision medicine: from science to value. Health Aff (Millwood) 37(5):694\u2013701","journal-title":"Health Aff (Millwood)"},{"key":"1498_CR7","doi-asserted-by":"publisher","unstructured":"Altamura C, Costa C, Fofi L et al (2020) Migraineurs' psychological traits do not influence response to erenumab. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-020-04661-6","DOI":"10.1007\/s10072-020-04661-6"},{"key":"1498_CR8","doi-asserted-by":"publisher","unstructured":"Vernieri F, Altamura C, Aurilia C et al (2020) Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-020-04669-y","DOI":"10.1007\/s10072-020-04669-y"},{"issue":"2","key":"1498_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: EARLY (ErenumAb in real life in ItalY), the first Italian multicenter, prospective real-life study. Headache. 61(2):363\u2013372","journal-title":"Headache."},{"key":"1498_CR10","doi-asserted-by":"publisher","unstructured":"Barbanti P, Aurilia C, Cevoli S et al (2021) Long term (48 weeks) effectiveness, safety and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in real-world: results of the EARLY 2 study. Headache. https:\/\/doi.org\/10.1111\/head.14194","DOI":"10.1111\/head.14194"},{"issue":"1","key":"1498_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Altamura C, Brunelli N et al (2021) GalcanezumAb for the prevention of high frequency episodic and chronic migraine in real life in ITaly: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 22(1):35. https:\/\/doi.org\/10.1186\/s10194-021-01247-1","journal-title":"J Headache Pain."},{"key":"1498_CR12","doi-asserted-by":"publisher","unstructured":"Vernieri F, Altamura C, Brunelli N et al (2021) Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15197","DOI":"10.1111\/ene.15197"},{"issue":"1","key":"1498_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-021-01333-4","volume":"22","author":"S Bottiroli","year":"2021","unstructured":"Bottiroli S, De Icco R, Vaghi G et al (2021) Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study. J Headache Pain. 22(1):114. https:\/\/doi.org\/10.1186\/s10194-021-01333-4","journal-title":"J Headache Pain."},{"issue":"1","key":"1498_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","volume":"22","author":"E Caronna","year":"2021","unstructured":"Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (2021) Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain. 22(1):120. https:\/\/doi.org\/10.1186\/s10194-021-01328-1","journal-title":"J Headache Pain."},{"issue":"2","key":"1498_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","volume":"36","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs 36(2):191\u2013202","journal-title":"CNS Drugs"},{"key":"1498_CR16","doi-asserted-by":"publisher","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15260","DOI":"10.1111\/ene.15260"},{"key":"1498_CR17","doi-asserted-by":"publisher","first-page":"774341","DOI":"10.3389\/fneur.2021.774341","volume":"12","author":"R Ornello","year":"2021","unstructured":"Ornello R, Baraldi C, Guerzoni S et al (2021) Gender differences in 3-month outcomes of Erenumab treatment\u2014study on efficacy and safety of treatment with Erenumab in men. Front Neurol 12:774341","journal-title":"Front Neurol"},{"issue":"1","key":"1498_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","volume":"22","author":"I Frattale","year":"2021","unstructured":"Frattale I, Caponnetto V, Casalena A et al (2021) Association between response to triptans and response to erenumab: real-life data. J Headache Pain. 22(1):1","journal-title":"J Headache Pain."},{"key":"1498_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache classification Committee of the International Headache Society","year":"2013","unstructured":"Headache classification Committee of the International Headache Society (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629\u2013808","journal-title":"Cephalalgia"},{"key":"1498_CR20","unstructured":"Gazzetta Ufficiale n.182, 21-7-2020"},{"issue":"14","key":"1498_CR21","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1177\/0333102416630579","volume":"36","author":"P Barbanti","year":"2016","unstructured":"Barbanti P, Aurilia C, Dall'Armi V, Egeo G, Fofi L, Bonassi S (2016) The phenotype of migraine with unilateral cranial autonomic symptoms documents increased peripheral and central trigeminal sensitization. A case series of 757 patients. Cephalalgia. 36(14):1334\u20131340","journal-title":"Cephalalgia."},{"key":"1498_CR22","doi-asserted-by":"publisher","first-page":"333102420929023","DOI":"10.1177\/0333102420929023","volume":"2","author":"P Barbanti","year":"2020","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Guadagni F, Ferroni P (2020) Dopaminergic symptoms in migraine: a cross-sectional study on 1148 consecutive headache center-based patients. Cephalalgia. 2:333102420929023. https:\/\/doi.org\/10.1177\/0333102420929023","journal-title":"Cephalalgia."},{"issue":"2","key":"1498_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/001316448604600202","volume":"46","author":"AB Silverstein","year":"1986","unstructured":"Silverstein AB (1986) Statistical power lost and statistical power regained: the Bonferroni procedure in exploratory research. Educational Phsycol Measur 46(2):303\u2013307","journal-title":"Educational Phsycol Measur"},{"issue":"4","key":"1498_CR24","doi-asserted-by":"publisher","first-page":"1000182","DOI":"10.4172\/2161-1459.1000182","volume":"5","author":"W Gaus","year":"2015","unstructured":"Gaus W, Mayer B, Muche R (2015) Interpretation of statistical significance - exploratory versus confirmative testing in clinical trials, epidemiological studies, Meta-analyses and toxicological screening (using Ginkgo biloba as an example). Clin Exp Pharmacol 5(4):1000182. https:\/\/doi.org\/10.4172\/2161-1459.1000182","journal-title":"Clin Exp Pharmacol"},{"key":"1498_CR25","unstructured":"(1999) ICH harmonised tripartite guideline statistical principles for clinical trials. International conference on harmonisation E9 expert working group. Stat Med 18(15):1905\u20131942"},{"issue":"4","key":"1498_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.5811\/westjem.2018.4.38383","volume":"19","author":"CE McCoy","year":"2018","unstructured":"McCoy CE (2018) Understanding the use of composite endpoints in clinical trials. West J Emerg Med 19(4):631\u2013634","journal-title":"West J Emerg Med"},{"key":"1498_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/B978-0-444-63233-3.00008-7","volume":"147","author":"T Bardakjian","year":"2018","unstructured":"Bardakjian T, Gonzalez-Alegre P (2018) Towards precision medicine. Handb Clin Neurol 147:93\u2013102","journal-title":"Handb Clin Neurol"},{"key":"1498_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/head.12498","volume":"55","author":"P Barbanti","year":"2015","unstructured":"Barbanti P, Egeo G (2015) Pharmacological trials in migraine: It\u2019s time to reappraise where the headache is and what the pain is like. Headache 55:439\u2013441","journal-title":"Headache"},{"issue":"10283","key":"1498_CR29","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Terwindt GM, Al-Karagholi MA, de Boer I, Lee MJ, Hay DL, Schulte LH, Hadjikhani N, Sinclair AJ, Ashina H, Schwedt TJ, Goadsby PJ (2021) Migraine: disease characterisation, biomarkers, and precision medicine. Lancet. 397(10283):1496\u20131504","journal-title":"Lancet."},{"issue":"6","key":"1498_CR30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/head.13510","volume":"59","author":"R Hargreaves","year":"2019","unstructured":"Hargreaves R, Olesen J (2019) Calcitonin gene-related peptide modulators - the history and renaissance of a new migraine drug class. Headache. 59(6):951\u2013970","journal-title":"Headache."},{"issue":"4","key":"1498_CR31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","volume":"158","author":"S Iyengar","year":"2017","unstructured":"Iyengar S, Ossipov MH, Johnson KW (2017) The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 158(4):543\u2013559","journal-title":"Pain."},{"issue":"5","key":"1498_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/head.13529","volume":"59","author":"S Iyengar","year":"2019","unstructured":"Iyengar S, Johnson KW, Ossipov MH, Aurora SK (2019) CGRP and the trigeminal system in migraine. Headache. 59(5):659\u2013681","journal-title":"Headache."},{"issue":"9","key":"1498_CR33","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/head.13635","volume":"59","author":"P Barbanti","year":"2019","unstructured":"Barbanti P, Egeo G, Mitsikostas DD (2019) Trigeminal-targeted treatments in migraine: is 60% the magic number? Headache. 59(9):1659\u20131661","journal-title":"Headache."},{"issue":"21","key":"1498_CR34","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1212\/01.wnl.0000262045.11646.b1","volume":"68","author":"ME Bigal","year":"2007","unstructured":"Bigal ME, Lipton RB, Holland PR, Goadsby PJ (2007) Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology. 68(21):1851\u20131861","journal-title":"Neurology."},{"issue":"2","key":"1498_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1358\/dnp.2010.23.2.1475909","volume":"23","author":"A Recober","year":"2010","unstructured":"Recober A, Goadsby PJ (2010) Calcitonin gene-related peptide: a molecular link between obesity and migraine? Drug News Perspect 23(2):112\u2013117","journal-title":"Drug News Perspect"},{"issue":"10","key":"1498_CR36","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrneurol.2013.180","volume":"9","author":"A Truini","year":"2013","unstructured":"Truini A, Garcia-Larrea L, Cruccu G (2013) Reappraising neuropathic pain in humans--how symptoms help disclose mechanisms. Nat Rev Neurol 9(10):572\u2013582","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"1498_CR37","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.pain.2014.08.014","volume":"155","author":"DT Demant","year":"2014","unstructured":"Demant DT, Lund K, Vollert J et al (2014) The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain. 155(11):2263\u20132273","journal-title":"Pain."},{"issue":"6","key":"1498_CR38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrneurol.2016.31","volume":"12","author":"J Olesen","year":"2016","unstructured":"Olesen J (2016) Migraine: are migraine endophenotypes needed? Nat Rev Neurol 12(6):320\u2013321","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"1498_CR39","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1046\/j.1526-4610.2003.03077.x","volume":"43","author":"P Barbanti","year":"2003","unstructured":"Barbanti P, Fabbrini G, Vanacore N, Pesare M, Buzzi MG (2003) Sumatriptan in migraine with unilateral cranial autonomic symptoms: an open study. Headache. 43(4):400\u2013403","journal-title":"Headache."},{"issue":"5","key":"1498_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10194-012-0440-y","volume":"13","author":"P Barbanti","year":"2012","unstructured":"Barbanti P, Fofi L, Dall'Armi V et al (2012) Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial. J Headache Pain 13(5):407\u2013414","journal-title":"J Headache Pain"},{"issue":"3","key":"1498_CR41","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1111\/ene.13550","volume":"25","author":"P Barbanti","year":"2018","unstructured":"Barbanti P, Egeo G (2018) Predictors of response to onabotulinumtoxin a in chronic migraine. Eur J Neurol 25(3):e40. https:\/\/doi.org\/10.1111\/ene.13550","journal-title":"Eur J Neurol"},{"issue":"3","key":"1498_CR42","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1468-2982.2005.01016.x","volume":"26","author":"P Sarchielli","year":"2006","unstructured":"Sarchielli P, Pini LA, Zanchin G et al (2006) Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia. 26(3):257\u2013265","journal-title":"Cephalalgia."},{"issue":"3","key":"1498_CR43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.pain.2006.09.012","volume":"125","author":"M Jakubowski","year":"2006","unstructured":"Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R (2006) Exploding vs. imploding headache in migraine prophylaxis with Botulinum toxin a. Pain. 125(3):286\u2013295","journal-title":"Pain."},{"issue":"1","key":"1498_CR44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1526-4610.2012.02288.x","volume":"53","author":"PM Grogan","year":"2013","unstructured":"Grogan PM, Alvarez MV, Jones L (2013) Headache direction and aura predict migraine responsiveness to rimabotulinumtoxin B. Headache. 53(1):126\u2013136","journal-title":"Headache."}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01498-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T02:02:38Z","timestamp":1667268158000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01498-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01498-6","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"assertion":[{"value":"13 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"138"}}